Plecanatide
Also known as: Plecanatide, RDX5791, SP-304, Trulance, uroguanylin analogue
Source Plecanatide at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Plecanatide is a synthetic 16‑amino‑acid peptide analog of uroguanylin approved for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation (IBS‑C). It is administered orally as a tablet.
Mechanism of Action
Activates intestinal guanylate cyclase-C receptors, increasing intracellular cGMP, which stimulates chloride and bicarbonate secretion and reduces sodium absorption, leading to increased intestinal fluid and accelerated transit.
Routes of Administration
Goals & Uses
- Abdominal pain/discomfort reduction in IBS-CPain / Symptom ManagementModerate
- Stool consistency improvementGastrointestinalHigh
- Relief of chronic idiopathic constipation (CIC)GastrointestinalHigh
- Chronic Idiopathic ConstipationGastrointestinalHigh
- Relief of irritable bowel syndrome with constipation (IBS-C)GastrointestinalHigh
- IBS‑C (Irritable Bowel Syndrome with Constipation)GastrointestinalHigh
Contraindications
- Known or suspected mechanical gastrointestinal obstructionGastrointestinalHigh
- Hypersensitivity to plecanatide or any excipientAllergic/ImmunologicHigh
- Pediatric patients under 6 years of ageAge RelatedHigh
- Pediatric patients <6 yearsAgeHigh
Adverse Effects
- Abdominal distensionGastrointestinalUncommon
- NauseaGastrointestinalUncommonFeeling of sickness or urge to vomit
- Upper respiratory tract infectionInfectiousUncommon
- FlatulenceGastrointestinalUncommonExcess gas in the digestive tract
- DiarrheaGastrointestinalCommonLoose or frequent stools
- DehydrationFluid BalanceRareLoss of body water or inadequate hydration
- Abdominal painGastrointestinalCommonPain or discomfort in the abdomen
Drug Interactions
- Other laxatives (e.g., polyethylene glycol, lactulose)Moderate
- No clinically significant drug interactions identifiedLow
- Anticholinergic agentsLow
Population Constraints
- PregnancyReproductive SafetyRelative
- Breastfeeding womenReproductiveRelative
- Severe diarrheaGastrointestinalRelative
- Pediatric patients (6 to <18 years)PediatricAbsolute
- Pregnant womenReproductiveRelative
- BreastfeedingReproductiveRelative
Regulatory Status
- European UnionApprovedApproved: Chronic Idiopathic ConstipationApproved by EMA (Trulance) for constipation; IBS‑C indication pending.
- United StatesApprovedApproved: Chronic Idiopathic Constipation, IBS‑CApproved by FDA in 2017 (Trulance).
- United KingdomUnapprovedNot approved by MHRA as of knowledge cutoff.
FDA approved January 2017 for CIC; expanded approval for IBS-C in January 2018. Carries a boxed warning contraindicating use in pediatric patients under 6 years due to risk of serious dehydration. Not approved in EU or UK as of knowledge cutoff.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Plecanatide?
Plecanatide is a synthetic 16‑amino‑acid peptide analog of uroguanylin approved for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation (IBS‑C). It is administered orally as a tablet.
What is Plecanatide used for?
Plecanatide is educationally associated with: Abdominal pain/discomfort reduction in IBS-C, Stool consistency improvement, Relief of chronic idiopathic constipation (CIC), Chronic Idiopathic Constipation, Relief of irritable bowel syndrome with constipation (IBS-C), IBS‑C (Irritable Bowel Syndrome with Constipation). Educational only — not medical advice.
How is Plecanatide administered?
Recorded routes of administration: Oral.
What are the potential side effects of Plecanatide?
Reported adverse effects include: Abdominal distension, Nausea, Upper respiratory tract infection, Flatulence, Diarrhea, Dehydration, Abdominal pain. This list is not exhaustive — consult a qualified clinician.
Who should avoid Plecanatide?
Recorded contraindications: Known or suspected mechanical gastrointestinal obstruction, Hypersensitivity to plecanatide or any excipient, Pediatric patients under 6 years of age, Pediatric patients <6 years. Consult a qualified clinician before use.